1009 Results

People

  1. Motzer
    Motzer
  2. O'Reilly
    O'Reilly
  3. Kris
    Kris
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Bajorin
    Bajorin
  7. Kelsen
    Kelsen
  8. Ginsberg
    Ginsberg
  9. Krug
    Krug
  10. Scher
    Scher

Groups

  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)
  7. Epidemiology and Biostatistics (119)
  8. Radiology, Department of (111)
  9. Biostatistics Service (109)
  10. GSK Faculty (104)
  1. "anemia"
Formats
  1. Journal Article (926)
  2. Review (42)
  3. Research Letter (15)
  4. Conference Paper (12)
  5. Editorial (4)
  6. Guidelines (3)
  7. Miscellaneous (3)
  8. Correspondence (2)
  9. Book Section (1)
  10. Meeting Abstract (1)
Groups
  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)

More Groups

People
  1. Robert Motzer (55)
  2. Eileen O'Reilly (35)
  3. Mark Kris (32)
  4. Carol Aghajanian (31)
  5. Clifford Hudis (31)
  6. Dean Bajorin (29)

More People

Years
  1. 2025 (41)
  2. 2024 (99)
  3. 2023 (56)
  4. 2022 (45)
  5. 2021 (25)
  6. 2020 (62)

More Years

Publications
  1. Journal of Clinical Oncology (69)
  2. Cancer (50)
  3. Clinical Cancer Research (49)
  4. Lancet Oncology (47)
  5. Gynecologic Oncology (34)
  6. Blood (29)

More Publications

Publishers
  1. Elsevier Inc. (147)
  2. Springer (90)
  3. Elsevier Science, Inc. (83)
  4. American Society of Clinical Oncology (74)
  5. Wiley Blackwell (65)
  6. Nature Publishing Group (61)

More Publishers

Results (1009)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 SELENE study: Ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
    Journal Article

    Nastoupil, L. J.; Hess, G.; Pavlovsky, M. A.; Danielewicz, I.; Freeman, J.; García-Sancho, A. M.; Glazunova, V.; Grigg, A.; Hou, J. Z.; Janssens, A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma
    Journal Article

    Strowd, R.; Ellingson, B.; Raymond, C.; Yao, J.; Wen, P. Y.; Ahluwalia, M.; Piotrowski, A.; Desai, A.; Clarke, J. L.; Lieberman, F. S.; more...
    Journal of Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
    Journal Article

    Kummar, S.; Shen, L.; Hong, D. S.; McDermott, R.; Keedy, V. L.; Casanova, M.; Demetri, G. D.; Dowlati, A.; Melcón, S. G.; Lassen, U. N.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Journal Article

    Nooka, A. K.; Cohen, A. D.; Lee, H. C.; Badros, A.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E. N.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Phase I study of entinostat, atezolizumab, carboplatin, and etoposide in previously untreated extensive-stage small cell lung cancer, ETCTN 10399
    Journal Article

    Gentzler, R. D.; Villaruz, L. C.; Rhee, J. C.; Horton, B.; Mock, J.; Hanley, M.; Kim, K.; Rudek, M. A.; Phelps, M. A.; Carducci, M. A.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Lesion dosimetry for [(177)Lu]Lu-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in patients with oligometastatic castration-sensitive prostate cancer
    Journal Article

    Grkovski, M.; O'Donoghue, J. A.; Imber, B. S.; Andl, G.; Tu, C.; Lafontaine, D.; Schwartz, J.; Thor, M.; Zelefsky, M. J.; Humm, J. L.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: Results of a phase II study (MOONSTONE/GOG-3032)
    Journal Article

    Randall, L. M.; O'Malley, D. M.; Monk, B. J.; Coleman, R. L.; Gaillard, S.; Adams, S.; Duska, L. R.; Dalton, H.; Holloway, R. W.; Huang, M.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial
    Journal Article

    Bahlis, N. J.; Costello, C. L.; Raje, N. S.; Levy, M. Y.; Dholaria, B.; Solh, M.; Tomasson, M. H.; Damore, M. A.; Jiang, S.; Basu, C.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial
    Journal Article

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Chari, A.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save